Literature DB >> 16454200

HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system.

Hai-Rong Shen1, Zhong-Dong Li, Ming-Kang Zhong.   

Abstract

A specific and accurate reversed-phase HPLC with UV detection was developed for the assay of atorvastatin in beagle dog plasma. Indomethacin was used as the internal standard. Atorvastatin was extracted by protein precipitation, the extracts were injected into a Kromasil C8 column (150 mm x 4.6 mm, 5 microm) with UV wavelength set at 270 nm. The mobile phase consisted of acetonitrile:0.1 mol/L ammonium acetate buffer (pH 4.0) (65:35% v/v) at a flow rate of 1.0 ml/min. The column was at ambient temperature (25 degrees C). The injection volume was 25 microl. The blank plasma did not interfere with the determination of atorvastatin and indomethacin. A good linear relationship was obtained between the peak area ratio of atorvastatin to indomethacin and the concentration of atorvastatin over the range of 0.05 to 2.5 microg/mL. The limit of quantification was 25 ng/mL, the limit of detection was 8 ng/ml. The total chromatographic analysis time was within 9 min. The method is accurate, precise and fast for the assay of atorvastatin in plasma following oral administration of an atorvastatin SMEDDS to healthy beagle dogs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454200

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  6 in total

1.  Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield
Journal:  Pharmacol Res       Date:  2010-12-27       Impact factor: 7.658

2.  Cloning/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classification of the canine OATP/SLCO members.

Authors:  Chunshan Gui; Bruno Hagenbuch
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2010-01-14       Impact factor: 3.228

3.  Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.

Authors:  A K Meena; D Venkat Ratnam; G Chandraiah; D D Ankola; P Rama Rao; M N V Ravi Kumar
Journal:  Lipids       Date:  2008-01-10       Impact factor: 1.880

4.  Stability Indicating RP-HPLC Estimation of Atorvastatin Calcium and Amlodipine Besylate in Pharmaceutical Formulations.

Authors:  D A Shah; K K Bhatt; R S Mehta; S L Baldania; T R Gandhi
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

5.  Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations.

Authors:  Farhad Ahmadi; Nasim Asaadi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

6.  Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain.

Authors:  Fabio Di Domenico; Marzia Perluigi; Eugenio Barone
Journal:  Neural Regen Res       Date:  2013-07-25       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.